Hodgkin Lymphocyte-Predominant Study - Phase III

Treatment of Children with Newly-Diagnosed Low-Stage Lymphocyte-Predominant Hodgkin Disease

Protocol Description

This Phase III Children's Oncology Group clinical trial is studying success rates of surgery and/or combination chemotherapy with or without radiation therapy or observation only in treating young patients with newly diagnosed Stage I or Stage II lymphocyte-predominant Hodgkin disease (LPHD). Researchers believe that if some people can be treated with less therapy or with surgery alone, then these people might have fewer side effects later in life.

Eligibility Criteria

Eligible candidates include boys and girls under the age of 21 with Hodgkin disease.
Boys: Up to age 21
Girls: Up to age 21

Treatment varies depending on each participant’s condition. Those with stage 1 LPHD with a lymph node completely removed at the time of diagnosis will be eligible for the observation-only part of the study. Stage I participants with whose lymph nodes are not completely removed will be subject to a chemotherapy regimen. All Stage II and Stage I LPHD in more than one lymph node will have chemotherapy and possibly radiation therapy, in accordance with the study protocol.
Visits: Varies depending on patient’s condition
Duration: Varies depending on treatment, however all participants’ medical condition will be followed for several years after treatment is completed.

Status: Open for Enrollment

Source of Support
Children’s Oncology Group (Study AHOD3P1)
National Cancer Institute

Additional Resources
Children’s Oncology Group CureSearch
Study Description at National Institutes of Health

Primary Investigator(s)

Peter H. Shaw, MD

Contact Information

To get started, please contact:
Peter Shaw, MD

Last Update
January 7, 2014
  • Increase/Decrease Text Size
  • Print This Page
Last Update
January 7, 2014